Management
Stéphane Degove
Co-founder
& Chief Executive Officer
Stéphane Degove
Co-founder & Chief Executive Officer
Stéphane is a biotech entrepreneur with a 25 years experience in pharma/biotech and strategy. He graduated from ESCP (majoring in Finance), worked at Sanofi in Finance and was co-founder and CFO in 2003 of a biotechnology company in cancer and thrombosis, Endotis Pharma. He co-founded in 2013 and was CEO of an immuno-oncology biotech, Gamamabs Pharma. Under his leadership, Endotis Pharma and GamaMabs Pharma raised € 70 million from international funds and built portfolios of innovative products developed up to Phase II.
Isabelle Richard, Ph. D
Co-founder
& Chief Scientific Officer
Isabelle Richard, Ph. D
Co-founder & Chief Scientific Officer
Dr. Isabelle RICHARD is a research Director at the CNRS. She is heading the Muscular Dystrophy team within the INSERM unit U951 at Genethon, Evry, France. Isabelle Richard is an expert in neuromuscular diseases and a pioneer in the research on LGMDs and in the development of gene therapy targeting LGMDs. She has published more than 160 scientific papers on muscular dystrophies. Among the most important highlights: identification of calpain 3 as the first gene implicated in an LGMD, demonstration of the heterogeneity of this group of diseases, participation in the identification of the gene of all the frequent LGMDs, proof-of-principle of the efficiency of gene therapy for all the most frequent LGMDs.
Sophie Olivier, MD
Chief Medical Officer
Sophie Olivier, MD
Chief Medical Officer
Sophie Olivier, MD, is responsible for clinical development strategy. Dr. Sophie Olivier has extensive clinical development experience in large and small pharma organizations and has overseen multiple regulatory interactions with both the FDA and the EMA. Prior to joining Atamyo, Dr. Olivier was Chief Medical Officer at Genticel (2014-2017) and more recently at Lysogene (2017-2021). In her position at Lysogene, Sophie Olivier oversaw clinical development of AAV gene therapies in rare neurodegenerative pediatric diseases. Before joining Genticel, Dr. Olivier worked as Scientific Officer in the Pediatric Team at the European Medicines Agency in London and led clinical developments in Women’s Health diseases at Wyeth Pharmaceutical, US (2000-2009). Dr. Sophie Olivier obtained MD degree and board certification in Obstetrics and Gynecology (summa cum laude) from the University of Marseille, France and M.Sc. in Biology of Reproduction from the University of Paris, France.
Catherine Cancian, MSc, MEng, MBA
Chief Technical Officer
Catherine Cancian, MSc, MEng, MBA
Chief Technical Officer
Catherine Cancian leads the Pipeline Process Development and Clinical Manufacturing. She has over 25 years’ experience in manufacturing operations and bioprocesses improvement in Biologicals with the last 7 years focused in Gene Therapy. Prior to joining Atamyo, Catherine was VP Pharmaceutical Operations for GenSight Biologics where she developed and executed the strategy for CMC and Supply Chain activities to support the clinical development and commercial readiness of AAV-based gene therapies. In 2015-2017, she was Industrialization Project Director for the setup of a new Gene and Cell Therapy manufacturing facility at YposKesi (formerly known as Genethon Bio production). Before that, she served at Sanofi Pasteur for 18 years at various management positions, leading multifunctional teams in Technology Transfer, Manufacturing readiness and CMC documentation for regulatory submissions in US and Europe for various marketed vaccines. She holds a BSc in Biochemistry & Molecular Biology, a MSc in Neurosciences, an Engineering Degree in Biotechnologies, as well as an MBA.
Board of Directors
Gene and Cell Therapy Institute at Mass General Brigham
Genethon
Genethon
Atamyo